Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared a post by Ben Derman, on X, Assistant Professor at University of Chicago, adding:
“Are VTE risk calculators for myeloma dead?
In short – likely yes. Limited relevance to modern setting, and apixaban/rivaroxaban are unquestionably better than aspirin. I agree with Ben and will start default DOACs even for VRd based MM regimens! (100% for K+IMiD)
And to add point that Ben Derman made separately, which I also agree with. For IMiD maintenance alone, ASA is fine and I still default here rather than DOAC (for long haul, ASA easier if procedures/operations planned). But for MM induction, DOACs are the way forward!”
Quoting Ben Derman’s post:
“One recommendation I make over and over is to use a prophylactic DOAC instead of aspirin in newly diagnosed myeloma.
Just choose a DOAC [they are getting much more affordable!]
- Risk scores lack validation for choosing VTE ppx.
- The BENEFIT trial shows 6-month incidence of VTE was 0.8% in patients receiving ppx DOAC vs 5.6% with ppx heparin, and 9.8% in patients receiving aspirin.”
Title: Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Authors: Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, Thomas Lecompte, Bernard Tardy, Ilhame Bounouara, Manon Sapet, Arthur Bobin, Stephanie Harel, Olivier Decaux, Karim Belhadj, Cyrille Touzeau, Margaret Macro, Mohamad Mohty, Philippe Moreau, Jill Corre, Hervé Avet-Loiseau, Lionel Karlin, Thierry Facon, Aurore Perrot, Cyrille Hulin, Salomon Manier, Laurent Frenzel, Xavier Leleu
More post from Rahul Banerjee on OncoDaily.